levofloxacin has been researched along with carbostyril in 148 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (carbostyril) | Trials (carbostyril) | Recent Studies (post-2010) (carbostyril) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 12,855 | 1,323 | 5,611 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (26.35) | 18.2507 |
| 2000's | 59 (39.86) | 29.6817 |
| 2010's | 33 (22.30) | 24.3611 |
| 2020's | 17 (11.49) | 2.80 |
| Authors | Studies |
|---|---|
| Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C | 1 |
| Citron, DM; Goldstein, EJ; Nesbit, CA | 1 |
| Jones, RN; Sutton, LD | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Cherubin, CE; Stratton, CW | 1 |
| Bale, MJ; Erwin, ME; Jones, RN | 1 |
| Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA | 1 |
| Houston, AK; Jones, RN | 1 |
| Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R | 1 |
| Foleno, BD; Fu, KP; Lafredo, SC | 1 |
| Allen, SD; Baker, CN; Barry, AL; Fuchs, PC; Hardy, DJ; Jorgensen, JH; Murray, PR; Tenover, FC | 1 |
| Hayakawa, I; Hohmura, M; Hoshino, K; Ishida, H; Kitamura, A; Nishino, T; Sato, K; Tanaka, M | 1 |
| Barbara-Burnham, L; Bermudez, LE; Inderlied, CB; Kolonoski, P; Wu, M; Young, LS | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Conejo, MC; García, I; Pascual, A; Perea, EJ; Salvador, J | 1 |
| Arvieux, C; Avril, JL; Cartier, F; Jacquelinet, C; Michelet, C; Vu, N | 1 |
| Ballesta, S; García, I; Pascual, A; Perea, EJ | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Ambrose, PG; Nightingale, CH; Owens, RC; Quintiliani, R | 1 |
| George, J; Morrissey, I | 1 |
| Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H | 1 |
| Inui, KI; Ito, T; Tanaka, K; Yano, I | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Bauernfeind, A | 1 |
| Izumi, K; Kawazoe, K; Mikamo, H; Sato, Y; Tamaya, T | 1 |
| Adamantidis, MM; Bordet, R; Caron, JF; Dumotier, BM | 1 |
| Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL | 1 |
| Domon, H; Miyazaki, S; Yamaguchi, K; Yoshizumi, S | 1 |
| Brookings, E; Gray, B; Nix, S; Robinson, A; Swiatlo, E; Waites, K | 1 |
| Callery-D'Amico, S; Cox, CE; Fowler, CL; Kim, SS; King, W; Klimberg, IW | 1 |
| Hashimoto, Y; Inui, K; Ito, T; Matsuo, Y; Yano, I | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H | 1 |
| Anjo, S; Hara, A; Nakamura, M; Sakai, M | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Haraoka, M; Kobayashi, I; Naito, S; Sagiyama, K; Saika, T; Tanaka, M | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Greenberg, RN; Newman, MT; Pectol, RW; Shariaty, S | 1 |
| Akaki, T; Kajitani, H; Sato, K; Shishido, S; Tomioka, H | 1 |
| Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Bonner, D; Fung-Tomc, J; Gradelski, E; Kolek, B; Valera, L | 1 |
| Barrett, JF; Chaniewski, S; Frosco, M; Hooper, DC; Lawrence, LE; Ryan, B; Yang, H | 1 |
| Baumann-Wilschke, I; Rücker, M; Shakibaei, M; Stahlmann, R | 1 |
| Barrett, JF; Frosco, M; Ho, H; Lawrence, LE; Mazzucco, CE; Ryan, BM; Warr, G | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Schaeffer, AJ | 1 |
| Furuhama, K; Itoh, S; Katoh, M | 1 |
| Frisbee-Hume, S; Ho, DH; LeBlanc, BM; Rolston, KV; Streeter, H | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Rubinstein, E | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Ono, C; Tanaka, M | 1 |
| Almer, LS; Balli, DJ; Beyer, JM; Cai, Y; Flamm, RK; Hensey-Rudloff, D; Nilius, AM; Shen, LL | 1 |
| Cars, O; Löwdin, E; Odenholt, I | 1 |
| Kawai, M; Mashima, Y; Mochizuki, H; Yamada, K; Yamada, M | 1 |
| Maĭchuk, IuF | 1 |
| Arakaki, N; Higa, F; Kawakami, K; Koide, M; Saito, A; Shinzato, T; Tateyama, M | 1 |
| Danziger, LH; Gunderson, SM; Hayes, RA; Quinn, JP | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Li, JL; Ma, XC; Tu, ZH; Xin, J; Zhang, T | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Arzamastsev, AP; Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Naber, KG | 1 |
| Gonoi, T; Saraya, A; Seino, S; Yokokura, M | 1 |
| Fish, DN | 1 |
| Kollef, MH; Shorr, AF; Susla, GB | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Hasegawa, M; Kobayashi, I; Koyama, H; Matsuzaki, K; Sato, Y; Watabe, E | 1 |
| Alferova, IV; Firsov, AA; Lubenko, IY; Portnoy, YA; Smirnova, MV; Zinner, SH | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Artemenko, N; Gorelov, A; Perekalina, T; Smelov, V; Smelova, N; Ukleeva, G | 1 |
| Kassab, NM; Kedor-Hackmam, ER; Santoro, MI; Singh, AK | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Hikida, M; Kariyama, R; Kato, Y; Kumon, H; Mikuniya, T; Monden, K | 1 |
| Ishikawa, K; Kawai, M; Mochizuki, H; Yamada, M | 1 |
| Pedro-Botet, L; Yu, VL | 1 |
| Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG | 1 |
| Bengoechea, JA; Campos, MA; Morey, P | 1 |
| Ni, YN; Zhang, GW | 1 |
| Andreeva, I; Rafalsky, V; Rjabkova, E | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Inui, K; Kimura, N; Okuda, M | 1 |
| Gualco, L; Marchese, A; Schito, AM; Schito, GC | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Esposito, S; Ianniello, F; Leone, S; Noviello, S | 1 |
| Barbone, F; De Maria, M; Giannarini, G; Manassero, F; Mogorovich, A; Morelli, G; Selli, C; Valent, F | 1 |
| Gigliotti, F; Morini, S; Ricci, C; Vaira, D; Zullo, A | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Cochetti, I; Minardi, D; Mingoia, M; Montanari, MP; Muzzonigro, G; Tili, E; Varaldo, PE | 1 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamamoto, Y; Yanagihara, K | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Bester, AJ; Chang, LW; Chang, YT; Chung, DT; Ho, ML; Hsu, MC; Kasumba, J; King, CH; Mitha, IH; Perng, RP; van Rensburg, DJ; Wu, RG | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Khawcharoenporn, T; Singh, K; Vasoo, S; Ward, E | 1 |
| Alarcón, E; Audícana, MT; Lobera, T; Longo, N; Muñoz, D; Navarro, B | 1 |
| Kessissoglou, DP; Kljun, J; Polatoglou, E; Psomas, G; Tarushi, A; Turel, I | 1 |
| Hu, M; Ledesma, KR; Singh, R; Swick, MC; Tam, VH; Yang, Z; Zechiedrich, L | 1 |
| Hosono, M; Takayanagi, R; Yamada, Y; Yokoyama, H | 1 |
| Calzetta, L; Cazzola, M; Fiori, E; Rogliani, P; Sabatini, M; Segreti, A; Segreti, V | 1 |
| Cho, JK; Kim, JH; Kim, KS | 1 |
| Cantón, R; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Moreno-Bofarull, A; Morosini, MI; Tato, M; Vila, J | 1 |
| Cantón, R; Espinal, P; Garcia-Alonso, F; Gargallo-Viola, D; López, Y; Tato, M; Vila, J | 1 |
| Chen, YH; Hsueh, PR; Huang, CH; Lai, CC | 1 |
| Cetinkaya, B; Demirdag, K; Denk, A; Kalkan, A; Kilic, SS; Ozden, M | 1 |
| Baba, T; Hiramatsu, K; Morimoto, Y; Sasaki, T | 1 |
| Cao, Z; Chang, L; Chen, P; Cui, S; Hu, C; Kuang, J; Li, J; Liang, Y; Liu, H; Liu, S; Liu, Y; Lv, X; Lv, Y; Ren, Z; Sun, S; Wang, C; Wang, D; Wang, X; Wu, J; Xiao, Z; Xiu, Q; Yang, H; Zhang, Y; Zhao, L; Zhu, D | 1 |
| Amano, A; Ikeda, F; Ishii, R; Kanayama, S; Matsumoto, S; Matsumoto, T; Matsuzaki, K; Nakajima, A; Okamoto, K | 1 |
| Das, A; Mandal, J; Natarajan, M | 1 |
| Chatzikonstantinou, M; Galani, I; Margaritis, A; Petrikkos, G; Souli, M | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Gotoh, N; Hayashi, N; Ikeda, F; Ishii, R; Kanayama, S; Matsumoto, T; Okamoto, K | 1 |
| Fey, PD; Fowler, RC; Iwen, PC; Murphy, CN; Williams, AJ | 1 |
| Amano, H; Hirano, T; Inoue, S; Kazamori, D; Kinoshita, T; Kuramoto, Y; Nishimura, K; Ohishi, K; Sakurai, A; Yazaki, A | 1 |
| Bruns, T; Büning, J; Fichtner-Feigl, S; Kruis, W; Maaser, C; Preiß, JC; Reuken, PA; Schmelz, R; Stallmach, A; Teich, N | 1 |
| Fang, G; Gao, J; Gao, X; Li, J; Liu, H; Liu, X; Lu, X; Tang, Y; Wang, J | 1 |
| Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Murata, M; Sasaki, D; Uno, N; Yamauchi, S; Yanagihara, K | 1 |
| Canton, R; García-Castillo, M; Gargallo-Viola, D; López, Y; Morrissey, I; Tato, M; Vila, J; Zsolt, I | 1 |
| Ehara, T; Haque, A; Huda, Q; Matsumoto, T; Miah, RA; Ohkusu, K; Okanda, T | 1 |
| Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D | 1 |
| Chang, LW; Chang, YT; Cheng, SL; Chuang, YC; Hsu, MC; Perng, WC; Tsao, SM; Wu, RG | 1 |
| Hashimoto, J; Hirose, T; Hiyama, Y; Hotta, H; Ichihara, K; Itoh, N; Kunishima, Y; Masumori, N; Matsukawa, M; Tachiki, H; Taguchi, K; Takahashi, S; Takeyama, K; Uehara, T; Yanase, M | 1 |
| Hidalgo, AA; Millanao, AR; Mora, AY; Mora, GC; Saavedra, CP; Valenzuela, LM; Villagra, NA | 1 |
| Ahn, J; Dawan, J; Ding, T; Kim, B; Kim, JC; Uddin, MJ | 1 |
| Fujisawa, M; Kitagawa, K; Nomi, M; Shigemura, K; Takami, N; Yamada, N | 1 |
| Andreu-Ros, I; Barrionuevo, E; Doña, I; Hernández Fernández de Rojas, D; López-Salgueiro, R; Martí-Garrido, J; Moreno, E; Pérez-Sánchez, N; Ruiz-San Francisco, A; Salas, M; Torres, MJ | 1 |
| Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ | 1 |
| Duque-Yemail, J; Grau-López, L; Palma-Alvarez, RF; Perea-Ortueta, M; Ramos-Quiroga, JA; Robles-Martínez, M; Ros-Cucurull, E | 1 |
| Cabañas, R; Domínguez-Ortega, J; Fiandor, A; González-Muñoz, M; Lluch-Bernal, M; Loli-Ausejo, D; Vílchez-Sánchez, F | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 1 |
| Hilden, P; Patel, N; Plotkin, S; Smoke, SM | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| Kim, EY; Kim, GR; Kim, SH; Shin, JH | 1 |
| Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
| Gunardi, WD; Moehario, LH; Nainggolan, IM; Nathania, I; Nusatia, ACM; Tjoa, E; Yasmon, A | 1 |
| Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Ahadi, H; Emami, S; Ghasemian, M; Ghassemi Barghi, N; Hosseini-Khah, Z; Shokrzadeh, M | 1 |
| Bartoletti, R; Cicione, A; DE Nunzio, C; Ficarra, V; Franco, A; Labella, M; Lombardo, R; Nacchia, A; Simonato, A; Trucchi, A; Tubaro, A | 1 |
| Nakaminami, H; Tanaka, E; Uchiya, KI; Wajima, T | 1 |
| Bulychev, VV; Bulycheva, EV; Pashkova, NA | 1 |
| Chen, W; Liang, B; Niu, H; Song, Z; Wang, Y; Xing, D; Zhang, Y | 1 |
15 review(s) available for levofloxacin and carbostyril
| Article | Year |
|---|---|
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
New generations of quinolones: with particular attention to levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones | 1997 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones; Sinusitis; Skin Diseases; Urinary Tract Infections | 1998 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prostatitis; Quinolones; Severity of Illness Index; Treatment Outcome; Urinary Tract Infections | 2004 |
Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.
Topics: Animals; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Quinolones; Respiratory Tract Infections; Staphylococcal Skin Infections | 2003 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; Meta-Analysis as Topic; Ofloxacin; Pneumonia, Bacterial; Quinolones; Randomized Controlled Trials as Topic | 2005 |
Legionella: macrolides or quinolones?
Topics: Animals; Anti-Infective Agents; Azithromycin; Clinical Trials as Topic; Humans; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2006 |
Quinolones for uncomplicated acute cystitis in women.
Topics: Acute Disease; Adult; Anti-Infective Agents, Urinary; Ciprofloxacin; Cystitis; Female; Fluoroquinolones; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Randomized Controlled Trials as Topic | 2006 |
[Treatment for Helicobacter pylori: current criteria].
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Metronidazole; Ofloxacin; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Tinidazole; Treatment Outcome | 2007 |
The potential role of nemonoxacin for treatment of common infections.
Topics: Anti-Bacterial Agents; Chlamydia Infections; Clostridium Infections; Community-Acquired Infections; Drug Therapy, Combination; Gonorrhea; Humans; Levofloxacin; Pneumonia, Bacterial; Quinolones; Skin Diseases, Bacterial | 2015 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
Efficacy of second-line regimens for
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline | 2020 |
Quinolone-induced psychosis: an updated review.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Delirium; Humans; Levofloxacin; Ofloxacin; Psychoses, Substance-Induced; Quinolones | 2020 |
Is EMA warning on quinolones and fluoroquinolones really assessed? An EudraVigilance database analysis.
Topics: Ciprofloxacin; Fluoroquinolones; Levofloxacin; Quinolones; Retrospective Studies | 2023 |
10 trial(s) available for levofloxacin and carbostyril
| Article | Year |
|---|---|
A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Quinolones; Urinary Tract Infections | 1998 |
Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Osteomyelitis; Quinolones | 2000 |
Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Dioxolanes; Double-Blind Method; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Prospective Studies; Prostatitis; Quinolones | 2007 |
Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
Topics: Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Quinolones; Treatment Outcome | 2010 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
The effect of indacaterol during an acute exacerbation of COPD.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Drug Therapy, Combination; Hospitalization; Humans; Indans; Ipratropium; Levofloxacin; Male; Methylprednisolone; Nebulizers and Vaporizers; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2013 |
A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haemophilus influenzae; Humans; Levofloxacin; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae; Treatment Outcome; Young Adult | 2017 |
Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Pneumonia, Bacterial; Quinolones; Safety; Treatment Outcome | 2019 |
Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Community-Acquired Infections; Double-Blind Method; Drug Combinations; Female; Fluoroquinolones; Humans; Levofloxacin; Lung Diseases; Male; Middle Aged; Pneumonia; Quinolones; Safety; South Africa; Taiwan; Treatment Outcome; Young Adult | 2019 |
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome | 2023 |
123 other study(ies) available for levofloxacin and carbostyril
| Article | Year |
|---|---|
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Isomerism; Isoniazid; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Splenomegaly; Survival Rate; Tuberculosis | 1995 |
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Wound Infection | 1995 |
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Topics: Ciprofloxacin; Diffusion; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Reproducibility of Results | 1995 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Assessment of the bactericidal activity of sparfloxacin, ofloxacin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes.
Topics: Ampicillin; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Listeriosis; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control S
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ceftizoxime; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quality Control; Quinolones; Reference Values; Spiro Compounds; Thienamycins | 1994 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Stereoisomerism; Tuberculosis, Pulmonary | 1994 |
Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Enterococcus faecalis; Escherichia coli; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1994 |
In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cricetinae; Fluoroquinolones; Humans; Levofloxacin; Lung; Mesocricetus; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Ofloxacin; Pneumonia, Mycoplasma; Quinolones | 1994 |
Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1993 |
Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
Topics: Anti-Infective Agents; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Ofloxacin; Quality Control; Quinolones | 1993 |
Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Culture Media; Culture Media, Serum-Free; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Kinetics; Levofloxacin; Metals; Microbial Sensitivity Tests; Microscopy, Electron; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Urine | 1996 |
Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
Topics: Animals; Anti-Infective Agents; Cell Line; Drug Combinations; Ethambutol; Female; Fluoroquinolones; Humans; Levofloxacin; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rats | 1996 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cisplatin; Doxorubicin; Fluoroquinolones; Humans; Levofloxacin; Neutrophils; Ofloxacin; Paclitaxel; Quinolones; Staphylococcus aureus | 1996 |
Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes.
Topics: Amoxicillin; Anti-Infective Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; HeLa Cells; Humans; Levofloxacin; Listeria monocytogenes; Ofloxacin; Quinolones; Rifampin; Sulfamethoxazole; Trimethoprim | 1997 |
[Uptake of 5 fluoroquinolones into human polymorphonuclear cells].
Topics: Anti-Infective Agents; Biological Transport; Fleroxacin; Fluorometry; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Levofloxacin; Neutrophils; Norfloxacin; Ofloxacin; Quinolones; Temperature | 1996 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Drug Eruptions; Fluoroquinolones; Gastrointestinal Diseases; Humans; Levofloxacin; Ofloxacin; Photosensitivity Disorders; Pneumonia; Quinolones | 1997 |
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Topics: Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Cats; Ciprofloxacin; Dogs; Fluoroquinolones; Haplorhini; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Swine; Wound Infection | 1997 |
The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1997 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones | 1997 |
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Daunorubicin; Epithelial Cells; Epithelium; Fluoroquinolones; Humans; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Quinolones; Swine | 1997 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Ofloxacin; Pneumococcal Infections; Quinolones; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae | 1997 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Disease Models, Animal; Drug Therapy, Combination; Endometritis; Escherichia coli; Female; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Rats; Rats, Sprague-Dawley | 1998 |
Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers.
Topics: Action Potentials; Animals; Anti-Infective Agents; Dose-Response Relationship, Drug; Female; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Male; Ofloxacin; Purkinje Fibers; Quinolones; Rabbits; Stereoisomerism | 1998 |
In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Streptococcus pneumoniae | 1998 |
Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Topics: Anti-Infective Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Streptococcus pneumoniae | 1998 |
Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Anti-Infective Agents; Cyclosporine; Epithelial Cells; Fluoroquinolones; Hydrogen-Ion Concentration; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Piperazines; Quinolones; Swine | 1998 |
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Virginiamycin | 1998 |
Comparison of the complexation of fluoroquinolone antimicrobials with metal ions by nuclear magnetic resonance spectroscopy.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Magnetic Resonance Spectroscopy; Metals; Ofloxacin; Quinolones; Solutions; Temperature | 1999 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Genotypic evolution in a quinolone-resistant Neisseria gonorrhoeae isolate from a patient with clinical failure of levofloxacin treatment.
Topics: Adult; Anti-Infective Agents; Chromosomes, Bacterial; DNA, Bacterial; Drug Resistance, Microbial; Genotype; Gonorrhea; Humans; Levofloxacin; Male; Neisseria gonorrhoeae; Ofloxacin; Polymerase Chain Reaction; Quinolones; Treatment Outcome | 1999 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: 4-Quinolones; Aminopyridines; Anti-Infective Agents; Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Rifamycins | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; beta-Lactams; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Indoles; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Staphylococcus aureus; Streptococcus; Vancomycin | 2001 |
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; Fluoroquinolones; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Staphylococcus aureus | 2002 |
Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Infective Agents; Calcium; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fluoroquinolones; In Vitro Techniques; Levofloxacin; Limb Buds; Magnesium; Male; Mice; Mice, Inbred Strains; Ofloxacin; Piperazines; Pregnancy; Quinolones | 2002 |
Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Blood Bactericidal Activity; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Indoles; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Sensitivity and Specificity; Staphylococcus aureus | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice.
Topics: Animals; Anti-Infective Agents; Chromosome Aberrations; Dose-Response Relationship, Drug; Fluoroquinolones; Levofloxacin; Light; Male; Mice; Mice, Hairless; Micronuclei, Chromosome-Defective; Micronucleus Tests; Ofloxacin; Photosensitizing Agents; Quinolones; Skin; Time Factors | 2002 |
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Sensitivity and Specificity | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Levofloxacin; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolones; Rabbits; Streptococcus pneumoniae | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Blood Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Protein Binding; Quinolones; Rats | 2003 |
Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Aqueous Humor; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Norfloxacin; Ofloxacin; Quinolones | 2003 |
[Levofloxacin (Tavanic) in the treatment of corneal ulcers].
Topics: Administration, Oral; Anti-Infective Agents; Corneal Ulcer; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Ofloxacin; Ophthalmic Solutions; Quinolones; Treatment Outcome | 2003 |
In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cell Line; Erythromycin; Fluoroquinolones; Guinea Pigs; Half-Life; Legionella; Legionnaires' Disease; Levofloxacin; Macrophages; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2003 |
In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 2004 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Compare two methods of measuring DNA damage induced by photogenotoxicity of fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Cells, Cultured; Ciprofloxacin; Comet Assay; Cricetinae; Cricetulus; DNA; DNA Damage; Fibroblasts; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Ultraviolet Rays | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Topics: Algorithms; Anti-Infective Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Models, Biological; Ofloxacin; Protein Binding; Quinolones; Staphylococcus aureus | 2004 |
Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Cells, Cultured; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Islets of Langerhans; Levofloxacin; Mice; Ofloxacin; Patch-Clamp Techniques; Potassium Channels; Quinolones | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
[Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Quinolones | 2005 |
Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Streptococcus pneumoniae; Time Factors | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome.
Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Chronic Disease; Fluoroquinolones; Humans; Levofloxacin; Male; Ofloxacin; Prostatitis; Quinolones | 2005 |
Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibiotics in pharmaceutical preparations by high-performance liquid chromatography.
Topics: Anti-Bacterial Agents; Calibration; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Ethylamines; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Models, Chemical; Models, Statistical; Ofloxacin; Pefloxacin; Pharmaceutical Preparations; Quinolones; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets; Temperature; Time Factors | 2006 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Fluoroquinolones; Fosfomycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones | 2005 |
Corneal penetration of simultaneously applied topical levofloxacin, norfloxacin and lomefloxacin in human eyes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Cornea; Female; Fluoroquinolones; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Norfloxacin; Ofloxacin; Quinolones; Tissue Distribution | 2006 |
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Levofloxacin; Male; Middle Aged; Ofloxacin; Pseudomonas Infections; Quinolones; Regression Analysis; Retrospective Studies; Risk Factors | 2006 |
Quinolones sensitize gram-negative bacteria to antimicrobial peptides.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Cell Membrane Permeability; Ciprofloxacin; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2006 |
[Synchronous fluorimetric determination of the residues of three quinolones in Eel by partial least squares].
Topics: Animals; Anti-Bacterial Agents; Drug Residues; Eels; Fluorometry; Fluoroquinolones; Least-Squares Analysis; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Seafood | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2.
Topics: Animals; Anti-Bacterial Agents; Biological Transport; Carbon Radioisotopes; Cell Line; Creatinine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levofloxacin; Molecular Structure; Ofloxacin; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyrrolidines; Quinolones; Transfection | 2006 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hemolysin Proteins; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Ultraviolet Rays; Urinary Tract Infections | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
[In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dioxolanes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus; Urinary Tract Infections | 2006 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Biofilms; Dose-Response Relationship, Drug; Enterococcus; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus; Stenotrophomonas maltophilia; Stents; Ureteral Calculi | 2008 |
Comparative mutant prevention concentration and mutant selection window of sitafloxacin versus other quinolones using strains of Haemophilus influenzae with decreasing susceptibility to levofloxacin.
Topics: Adaptation, Biological; Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Mutation; Ofloxacin; Quinolones; Selection, Genetic | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
High rates of quinolone resistance among urinary tract infections in the ED.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Quinolones; Retrospective Studies; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections; Young Adult | 2012 |
Allergy to quinolones: low cross-reactivity to levofloxacin.
Topics: Adult; Aged, 80 and over; Basophils; Cross Reactions; Drug Hypersensitivity; Female; Flow Cytometry; Humans; Hypersensitivity, Immediate; Levofloxacin; Male; Middle Aged; Ofloxacin; Quinolones; Skin Tests; Young Adult | 2010 |
Interaction of Zn(II) with quinolone drugs: structure and biological evaluation.
Topics: Animals; Anti-Bacterial Agents; Cattle; Coordination Complexes; Crystallography, X-Ray; DNA; Fluoroquinolones; Humans; Levofloxacin; Models, Molecular; Ofloxacin; Protein Binding; Quinolones; Serum Albumin; Serum Albumin, Bovine; Zinc | 2011 |
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Gene Deletion; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Polymerase Chain Reaction; Quinolones; Real-Time Polymerase Chain Reaction | 2012 |
Interactions between new quinolone antibacterials and diagnostic drug containing manganese.
Topics: Algorithms; Anti-Bacterial Agents; Chelating Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Interactions; Levofloxacin; Manganese Compounds; Ofloxacin; Quinolones | 2013 |
Prevalence and characterization of plasmid-mediated quinolone resistance genes in Salmonella isolated from poultry in Korea.
Topics: Animals; Blotting, Southern; Ciprofloxacin; DNA Primers; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Gene Transfer, Horizontal; Levofloxacin; Microbial Sensitivity Tests; Nalidixic Acid; Plasmids; Polymerase Chain Reaction; Poultry; Poultry Diseases; Quinolones; Republic of Korea; Salmonella; Salmonella Infections, Animal | 2013 |
Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Hydrogen-Ion Concentration; Levofloxacin; Microbial Sensitivity Tests; Quinolones | 2014 |
In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
Topics: Aminopyridines; Anti-Bacterial Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Quinolones; Selection, Genetic; Sequence Analysis, DNA | 2015 |
In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Topics: Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Doxycycline; Fluoroquinolones; Humans; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolones; Serotyping; Turkey | 2015 |
Apigenin as an anti-quinolone-resistance antibiotic.
Topics: Anti-Bacterial Agents; Apigenin; Base Sequence; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Quinolones; Sequence Analysis, DNA; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase II Inhibitors | 2015 |
In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Topics: Administration, Cutaneous; Adolescent; Adult; Aminopyridines; Anti-Bacterial Agents; Child; Female; Fluoroquinolones; Humans; Japan; Levofloxacin; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Quinolizines; Quinolones; Skin Cream; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Streptococcus pyogenes | 2016 |
The Emergence of Quinolone Resistant Shigella sonnei, Pondicherry, India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Bacterial; Dysentery, Bacillary; Feces; Humans; India; Levofloxacin; Microbial Sensitivity Tests; Plasmids; Quinolones; Shigella sonnei | 2016 |
Plasmid-mediated quinolone resistance determinants among Gram-negative bacteraemia isolates: a hidden threat.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Gram-Negative Bacterial Infections; Greece; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Quinolones; R Factors; Stenotrophomonas maltophilia | 2017 |
Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
Topics: Aminopyridines; Anti-Bacterial Agents; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Propionibacterium acnes; Quinolones | 2017 |
Nontyphoidal Salmonella enterica Nonsusceptible to Both Levofloxacin and Ceftriaxone in Nebraska, United States 2014-2015.
Topics: Anti-Bacterial Agents; Ceftriaxone; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Nebraska; Quinolones; Salmonella enterica; Sequence Analysis, DNA; Serotyping; Specimen Handling | 2018 |
Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Quinolones; Structure-Activity Relationship | 2018 |
Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Antifungal Agents; beta-Lactamase Inhibitors; Candida albicans; Carbapenems; Cephalosporins; Crohn Disease; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterococcus; Female; Germany; Humans; Immunosuppressive Agents; Intestinal Perforation; Length of Stay; Levofloxacin; Male; Penicillins; Prospective Studies; Quinolones; Registries; Streptococcus; Young Adult | 2018 |
Upconversion particle@Fe
Topics: Animals; Biosensing Techniques; Ciprofloxacin; Enoxacin; Enrofloxacin; Erbium; Fishes; Fleroxacin; Fluorescent Dyes; Fluorides; Fluoroquinolones; Levofloxacin; Magnetite Nanoparticles; Molecular Imprinting; Quinolones; Reproducibility of Results; Seafood; Ytterbium; Yttrium | 2018 |
Topics: Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Quinolones; Streptococcus pneumoniae | 2018 |
Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Topics: Aminopyridines; Anti-Bacterial Agents; Humans; Impetigo; Levofloxacin; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Quinolones; Staphylococcaceae; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2018 |
Characteristics of Resistance Mechanisms and Molecular Epidemiology of Fluoroquinolone-Nonsusceptible
Topics: Anti-Bacterial Agents; Bangladesh; Cross Infection; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Mutation; Quinolones; Salmonella enterica; Salmonella Infections; Salmonella paratyphi A; Tertiary Care Centers; Typhoid Fever | 2018 |
Selective culture of Escherichia coli to prevent infective complications of transrectal ultrasound-guided prostate biopsy: Clinical efficacy and analysis of characteristics of quinolone-resistant Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Image-Guided Biopsy; Japan; Levofloxacin; Logistic Models; Male; Microbial Sensitivity Tests; Prospective Studies; Prostate; Quinolones; Rectum; Treatment Outcome; Ultrasonography, Interventional | 2019 |
Cysteine auxotrophy drives reduced susceptibility to quinolones and paraquat by inducing the expression of efflux-pump systems and detoxifying enzymes in S. Typhimurium.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cysteine; Drug Resistance, Multiple, Bacterial; Gene Deletion; Gene Expression; Genes, Bacterial; Humans; Levofloxacin; Membrane Transport Proteins; Mutation; Nalidixic Acid; Paraquat; Quinolones; Reactive Oxygen Species; Salmonella typhimurium; Sulfur | 2019 |
Assessment of antibiotic resistance in bacteriophage-insensitive Klebsiella pneumoniae.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteriophages; beta-Lactamases; Cefotaxime; Cephalothin; Chloramphenicol; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Humans; Klebsiella pneumoniae; Levofloxacin; Phage Therapy; Quinolones | 2019 |
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Cefdinir; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Hospitals, Rehabilitation; Humans; Japan; Levofloxacin; Male; Middle Aged; Outpatients; Quinolones; Retrospective Studies; Spinal Cord Injuries; Urinary Bladder, Neurogenic; Young Adult | 2020 |
Clinical Characterization and Diagnostic Approaches for Patients Reporting Hypersensitivity Reactions to Quinolones.
Topics: Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Levofloxacin; Quinolones; Skin Tests | 2020 |
Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Basophil Degranulation Test; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Quinolones; Skin Tests; Young Adult | 2021 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Use and Resistance at an Urban Teaching Hospital.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Hospitals, Teaching; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Oxacillin; Pseudomonas aeruginosa; Quinolones; Retrospective Studies; Staphylococcus aureus | 2022 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
Characteristics of Clonal Complex Changes and Quinolone Resistance-Determining Region Mutations of Levofloxacin-Resistant
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Quinolones; Streptococcus pneumoniae | 2022 |
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
Topics: Amino Acids; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Quinolones; Salmonella; Salmonella enterica; Salmonella typhi; Typhoid Fever | 2022 |
Conversion of antibacterial quinolone drug levofloxacin to potent cytotoxic agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Proliferation; Cytotoxins; Drug Screening Assays, Antitumor; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Molecular Structure; Quinolones; Structure-Activity Relationship | 2023 |
Contribution of amino acid substitutions in ParE to quinolone resistance in Haemophilus haemolyticus revealed through a horizontal transfer assay using Haemophilus influenzae.
Topics: Agar; Amino Acid Substitution; Anti-Bacterial Agents; Child; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Quinolones | 2023 |
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19].
Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis | 2023 |
High antipersister activity of a promising new quinolone drug candidate in eradicating uropathogenic Escherichia coli persisters and persistent infection in mice.
Topics: Animals; Biofilms; Levofloxacin; Mice; Persistent Infection; Quinolones; Uropathogenic Escherichia coli | 2023 |